Using Multi-Omic Markers to Track Intermediate Biological Responses in Human Longevity Trials

On 2026-09-30, CNN reported on FAST, short for “Finding Aging Biomarkers by Searching Existing Trials.” The coverage featured Daniel Belsky, an associate professor of epidemiology at Columbia University, discussing the search for biological indicators that respond to interventions.

Why FAST focuses on change rather than a single age estimate

FAST addresses a measurement problem at the center of longevity research: how to assess whether an intervention affects aging biology. According to CNN’s reporting, the project examines proteins and metabolites alongside epigenetic marks in white blood cells. Its focus is on finding indicators that respond to interventions rather than relying only on a biological-age estimate taken at one point in time. The potential contribution to healthspan research is a way to track biological responses while researchers investigate the longer-term question of whether targeting aging helps people remain healthy.

Human research: FAST concerns biomarkers in existing human intervention trials, not an in vitro or animal experiment.

How to interpret FAST without getting ahead of the evidence

• The coverage describes a research objective rather than a completed demonstration. CNN’s account presents FAST as a search for useful indicators of intervention response. It does not report FAST results establishing that an intervention slowed aging or prevented age-related disease. The immediate news is therefore about how researchers hope to evaluate interventions, not about a treatment reaching a health or longevity milestone.

That distinction determines the appropriate headline and takeaway. A project designed to improve measurement belongs in a different category from a trial reporting better health outcomes. Readers assessing FAST should look first for what the project has actually measured and reported, rather than treating its long-term purpose as an accomplished result.

• A responsive biomarker still needs a connection to future health. Follow-up reporting on FAST describes Belsky’s concern that researchers do not yet know whether changes in these markers indicate longer life or better health. A measurement could register an intervention’s biological effects without establishing what those effects mean for the person receiving it. Responsiveness and health relevance are therefore separate questions.

The reporting describes a possible role for validated biomarkers as intermediate trial outcomes. In that role, a measurement would help researchers assess an intervention before all long-term health outcomes become available. The important validation step is connecting the measured change to what eventually happens to people. For readers comparing studies, the useful question is not simply whether a marker changed but what evidence connects that change to a meaningful outcome.

• Multiple kinds of data do not automatically create a validated aging test. FAST’s reported approach includes proteins and metabolites as well as epigenetic marks. This makes it a multi-omic effort, meaning that it examines different kinds of molecular information together. The breadth of those measurements is a feature of the research design rather than a finding about how accurately a finished test performs.

The distinction matters when a description moves from collecting complementary signals to claiming that a combined score measures aging itself. An assessment should ask how the measurements contribute to the research question and how their interpretation is checked against outcomes. AgeAmaze’s guide to the different molecular signals used in aging models provides context for reading those descriptions. In FAST’s case, the relevant focus is the search for useful response indicators rather than the appeal of a single final number.

• An intervention-related clock change may be difficult to separate from a disease-related effect. A separate 2026 paper in Nature Biotechnology examined six proteomic aging clocks using serum samples from a phase 2a trial of rentosertib for idiopathic pulmonary fibrosis. A summary of that paper reported that all six clocks predicted lower biological age in treated groups. That analysis was separate from FAST and should not be presented as one of its results.

The same summary cautioned that proteomic clocks alone could not distinguish aging-related effects from effects specific to the disease or treatment. This is an interpretation problem even when several clocks point in the same direction. Agreement between measurements does not settle which biological process produced the signal. When reading this kind of trial analysis, the practical task is to identify the measured change and then examine the evidence offered for its proposed explanation.

• The broader hypothesis of targeting aging requires its own human test. In CNN’s coverage, Belsky said that the idea of targeting aging had not yet been tested in humans. He also argued that existing evidence provided a reason to test it. His statement separates the scientific rationale for conducting research from evidence that the proposed strategy works in people.

FAST fits into that distinction as an effort to improve the tools available for research. The measurement question is which indicators might help evaluate an intervention; the broader question is whether targeting aging reduces disease or improves healthy lifespan. Those questions belong to the same research agenda without being interchangeable. Readers can use that separation to assess whether a report concerns a measurement tool or a demonstrated health benefit, rather than treating every development as the same kind of progress.

• Research biomarkers do not establish the medical usefulness of consumer age scores. Stanford Medicine reports that direct-to-consumer biological-age clocks are not FDA-approved medical diagnostic tools and are not used clinically by mainstream clinicians. FAST’s research purpose should therefore not be treated as an endorsement of a commercial test. Evaluating a potential research measure and deciding whether a test should guide an individual’s care are different decisions.

For readers considering testing, the grounded takeaway is to treat a biological-age score as an estimate rather than a treatment verdict. AgeAmaze’s explanation of the distinction between an aging estimate and a medical diagnostic result offers a framework for assessing such claims. Personal decisions about testing or treatment belong with a qualified clinician. The FAST reporting provides a reason to follow biomarker research rather than a basis for selecting a therapy from a change in an age score.

Taken together, these distinctions suggest a practical way to read the next FAST update: identify the outcome before judging the claim. A report might concern the selection of candidate indicators or their response to an intervention. Another might examine how those responses relate to later health. Keeping the reported outcome visible makes the research easier to assess on its own terms.

The next question is what decision the evidence is being asked to support. Selecting a marker for further investigation is different from using it to evaluate an intervention or guide care. A clear account should make that intended use explicit. This approach gives promising measurement work appropriate attention without assigning it a role it has not yet earned.

For the broader context, AgeAmaze’s guide to evaluating claims that an intervention slows aging offers a related reading framework. The useful habit is to keep the measurement, the proposed interpretation and the claimed benefit separate while following how the evidence develops.

How to judge the next phase of FAST

The next decisive step is to test whether intervention-responsive biomarkers reliably predict subsequent health outcomes, giving researchers a firmer basis for evaluating whether targeting aging improves human healthspan.

How AgeAmaze helps

Assessing whether FAST strengthens a biological-age claim requires careful interpretation, and AgeAmaze helps readers work through that judgment with research-led explanations. Its coverage addresses overstated claims about biomarkers and emerging interventions so research-minded adults can distinguish established findings from promising proposals and speculation about healthy aging.

Read the research

Sources

1. 383ff4bf researchers test whether
2. Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
3. Can aging be treated like a disease? Scientists are starting ...
4. Integration of proteomic aging… — Sound, with caveats
5. med.stanford.edu · news · insightsBiological age versus chronological age: What the science says